Catalog No.
Product Name
Application
Product Information
Citations
-
HIV-1 Inhibitor
U-75875 is an HIV-1 protease inhibitor that effectively impedes the processing of Gag-Pol proteins, thereby disrupting viral maturation and replication. This compound is primarily utilized in research focused on HIV-1 infection, providing valuable insights into viral life cycle mechanisms and potential therapeutic interventions. -
HIV-1 Protease Inhibitor
HIV-1 protease-IN-11 is a potent HIV-1 protease inhibitor with an IC50 value of 0.41 nM. This compound demonstrates significant efficacy against drug-resistant variants of the virus, offering opportunities for HIV research and therapeutic development. Its selective targeting of the HIV-1 protease positions it as a valuable tool in the study of HIV replication and infection mechanisms. -
HIV Protease
JG-365 is a potent inhibitor of HIV-1 protease that targets the enzyme's active site, effectively blocking its activity. This compound exhibits significant antiviral activity, making it a valuable tool for research in HIV infection and therapeutic development. Its ability to disrupt the replication cycle of HIV-1 provides insights into potential treatment strategies against HIV-related diseases. -
HIV Proteinase Inhibitor
AG-1284 is an effective HIV proteinase inhibitor, demonstrating an EC50 of 0.5 mg/mL. This compound is utilized in research focused on HIV infection mechanisms and therapeutic strategies aimed at viral suppression. AG-1284's inhibition of HIV proteinase makes it a valuable tool for studying the virus's replication cycle and potential drug development. -
HIV Protease Inhibitor
A-77003 is a potent HIV protease inhibitor, demonstrating an IC50 range of 0.1 to 0.2 μg/ml against both HIV-1 and HIV-2 proteases. This compound exhibits significant antiretroviral activity while maintaining low cytotoxicity in vitro, making it suitable for research applications focused on HIV treatment and therapeutic development. -
HIV-1 Protease Inhibitor
A 74704 is a pseudo C2-symmetric inhibitor targeting HIV-1 protease. This compound effectively disrupts the enzymatic activity of the protease, thereby inhibiting viral replication. It serves as a valuable reagent for studying HIV pathogenesis and developing antiviral therapies. -
HIV-1 Protease Inhibitor
A-80987 is a selective inhibitor of human immunodeficiency virus type 1 (HIV-1) protease. This compound effectively disrupts the proteolytic processing of viral polyproteins, thereby hindering viral replication. A-80987 is valuable for research focused on HIV pathogenesis and therapeutic interventions targeting viral enzyme activity. -
HIV-1 Reverse Transcriptase Inhibitor
Opaviraline is a potent HIV-1 reverse transcriptase inhibitor. It effectively disrupts the viral replication process by targeting the reverse transcriptase enzyme, which is crucial for converting viral RNA into DNA. This compound is utilized in research focused on developing antiviral therapies and understanding HIV-1 resistance mechanisms. -
HIV Protease Inhibitor
Ro 31-8588 is a potent HIV protease inhibitor, exhibiting a Ki of 0.3 nM. This compound is essential for studying the role of HIV protease in viral replication and can be utilized in research focused on AIDS treatment and potential therapeutic strategies. Its high affinity makes it a valuable tool for investigating the mechanistic aspects of HIV inhibition. -
HIV Protease Control
Hydroxy darunavir is a metabolite of the HIV-1 protease inhibitor darunavir, targeting the HIV protease to inhibit viral replication. It plays a significant role in understanding the pharmacokinetics and metabolism of darunavir and can be utilized in research applications aimed at studying HIV resistance mechanisms and therapeutic efficacy. This compound is essential for investigations into antiviral drug development and optimization strategies. -
HIV-1 Protease Inhibitor
LY-289612 is a potent HIV-1 protease inhibitor, exhibiting an IC50 value of 1.5 nM. This compound effectively disrupts the proteolytic processing of viral polyproteins, thereby inhibiting the replication of HIV-1. It is utilized in research focused on developing antiviral therapies and understanding HIV resistance mechanisms. -
HIV-1 Protease Inhibitor
PL-100 is a powerful inhibitor of HIV-1 protease, exhibiting a Ki of 36 pM and an EC50 of 16 nM. This compound effectively inhibits viral replication by targeting HIV-1 protease activity, showing significant antiviral efficacy against drug-resistant strains of the virus. PL-100 is suitable for research applications focused on understanding and combating drug-resistant HIV infections. -
HIV Replication Inhibitor
PMEDAP is a potent inhibitor of human immunodeficiency virus (HIV) replication, demonstrating significant antiviral activity. In addition to its efficacy against HIV, PMEDAP exhibits anti-murine cytomegalovirus (MCMV) properties and effectively inhibits Moloney murine sarcoma virus (MSV)-induced tumor formation and associated mortality. This compound is valuable for research applications focused on viral pathogenesis and therapeutic interventions in retroviral infections. -
Anti-HIV Synthetic Peptides
T-22 is an anti-HIV synthetic peptide that specifically targets viral entry by disrupting the fusion process of the virus with host cells. Demonstrating potent antiviral activity with an EC50 of 0.008 μg/mL, T-22 exhibits a CC50 of 54 μg/mL, indicating its relative safety for cellular application. In addition to its antiviral properties, T-22 has been shown to enhance plant growth, photosynthesis, total chlorophyll content, and gas exchange in tomatoes, as well as provide resistance against Cucumber Mosaic Virus (CMV). This multifunctional peptide serves as a valuable tool in both virology and agricultural research. -
HIV Protease Inhibitor
2α,19α-Dihydroxy-3-oxo-urs-12-en-28-oic acid is identified as a potent inhibitor of HIV protease, exhibiting significant antiviral activity. Additionally, this compound inhibits the activation of Epstein-Barr virus early antigen (EBV-EA), demonstrating its utility in virology research. Furthermore, it displays inhibitory effects on nitric oxide production in lipopolysaccharide-activated RAW 264.7 cells, highlighting its potential applications in immunology and inflammation studies. -
HIV/EV-A71 Inhibitor
AL-470 is a potent antiviral compound targeting HIV-1, HIV-2, and EV-A71, exhibiting EC50 values of 0.27 µM, 0.63 µM, and 0.35 µM, respectively. This compound demonstrates significant inhibition of viral replication and is suitable for studies focused on HIV and enterovirus A71 infections. AL-470 serves as a valuable tool for researchers investigating antiviral mechanisms and therapeutic strategies against these viral pathogens. -
HIV/HBV Inhibitor
Emtricitabine triphosphate tetrasodium salt is the tetrasodium salt form of Emtricitabine triphosphate, a phosphorylated metabolite of Emtricitabine. This compound functions as a nucleoside reverse transcriptase inhibitor, effectively targeting both HIV and HBV. Emtricitabine triphosphate tetrasodium salt is utilized in research applications focused on antiviral drug development and the mechanisms of viral replication. -
HIV Inhibitor
(S)-Tenofovir is an S-enantiomer of Tenofovir, functioning primarily as a nucleotide reverse transcriptase inhibitor. This compound demonstrates significant biological activity against HIV and is also relevant in the treatment of chronic Hepatitis B (HBV). It is commonly utilized in research applications focused on antiviral therapies and the mechanistic study of retroviral infections. -
HIV/HBV Inhibitor
L-Fd4A is an adenine derivative that inhibits both human immunodeficiency virus (HIV) and hepatitis B virus (HBV) with effective concentrations (EC50) of 1.5 μM and 1.7 μM, respectively. This compound demonstrates promising antiviral activity while exhibiting low cytotoxicity, making it suitable for research applications in studying HIV and HBV inhibition mechanisms. -
anti-HBV/HIV-1 Agent
Periglaucine A is a hasubanane-type alkaloid that targets anti-HBV and anti-HIV-1 activity. It effectively inhibits the secretion of HBV surface antigen (HBsAg) in Hep G2.2.15 cells, demonstrating its potential as a therapeutic agent against hepatitis B virus. Additionally, Periglaucine A exhibits anti-HIV-1 efficacy in C8166 cells, with an EC50 value of 204 μM, making it a valuable compound for research in viral infections. -
HCV/HIV Inhibitor
C5A is a microbicidal peptide that targets and inhibits both hepatitis C virus (HCV) and human immunodeficiency virus (HIV). By disrupting the membrane integrity of the HIV virion and affecting the conical capsid core that encases the viral genome, C5A significantly reduces the infectivity of a wide range of HIV isolates in various primary target cells in vitro. Additionally, studies have demonstrated that C5A offers protective effects in mice against vaginal and rectal challenges with HIV, highlighting its potential utility in antiviral research applications. -
HIV-1 Integrase Inhibitor
GSK-1264 is an HIV-1 integrase inhibitor that targets the catalytic core and C-terminal domains of the HIV-1 integrase enzyme. By promoting the formation of an open polymer structure of integrase dimers, GSK-1264 disrupts the late stages of HIV replication and interferes with viral particle assembly. This compound is valuable for research focused on HIV infection and understanding integrase-mediated processes in the viral life cycle. -
HIV-1 Integrase Inhibitor
HIV-1 Integrase Inhibitor 8 is a selective inhibitor targeting the HIV-1 integrase enzyme. It demonstrates potent activity against viral replication by disrupting the integration of viral DNA into the host genome, which is essential for the HIV life cycle. This compound is primarily utilized in research focused on antiretroviral therapy and the development of HIV treatments, contributing to the understanding of integrase inhibition mechanisms. -
HIV-1Integrase Inhibitor
GSK3839919A is a potent allosteric inhibitor of HIV-1 integrase, targeting the enzyme responsible for the integration of viral DNA into the host genome. This compound exhibits significant antiviral activity against HIV-1, making it a valuable tool for research applications focused on the development of novel antiretroviral therapies and the study of HIV replication mechanisms. Its unique mechanism of action may provide insights into resistance pathways and inform drug design strategies. -
HIV Integrase Inhibitor
His-Cys-Lys-Phe-Trp-Trp is an HIV integrase inhibitor, exhibiting an IC50 of 2 μM. This compound impedes the integrase enzyme's function, thereby preventing viral DNA integration into the host genome. His-Cys-Lys-Phe-Trp-Trp is valuable for research focused on HIV pathogenesis and the development of antiretroviral therapies. -
HIV-1 integrase Inhibitor
(S)-BI-1001 is a potent HIV-1 integrase inhibitor, demonstrating significant antiviral activity. It exhibits an IC50 value of 28 nM, an EC50 of 450 nM, and a Kd of 4.7 μM, indicating its efficacy in disrupting viral replication processes. This compound is valuable for research applications focused on HIV-1 pathogenesis and therapeutic development. -
HIV-1 Integrase Inhibitor
HIV-1 Integrase Inhibitor 7 is a potent inhibitor of HIV-1 integrase, exhibiting an IC50 value of 33.3 nM. This compound effectively interferes with the integration of viral DNA into the host genome, making it essential for studies focused on HIV-1 replication and treatment strategies. It serves as a valuable tool in research applications aimed at understanding HIV-1 biology and developing therapeutic interventions against HIV. -
HIV-1 Integrase Inhibitor
HIV-1 Integrase Inhibitor 11 is a potent inhibitor of HIV-1 integrase, demonstrating an IC50 of 125 μM. This compound effectively disrupts the integration of viral DNA into the host genome, thereby hindering the replication process of HIV-1. It is suitable for research applications aimed at developing antiretroviral therapies and studying the mechanisms of HIV integration and resistance. -
HIV-1 IN/RT RNase H Inhibitor
2-Hydroxyisoquinoline-1,3(2H,4H)-dione is an inhibitor of HIV-1 integrase (IN) and reverse transcriptase (RT) ribonuclease H (RNase H), demonstrating IC50 values of 6.32 µM and 5.9 µM, respectively. This compound serves as a valuable tool for studying HIV-1 replication and provides insights into the inhibition mechanisms of viral enzymes. Its biological activity and specificity make it useful for research applications focused on antiviral drug development and understanding HIV-1 pathogenesis. -
HIV Integrase Inhibitor
L-870812 is an HIV integrase inhibitor that targets the strand transfer mechanism of HIV-1 integration. This compound effectively blocks both cell-free and cell-associated HIV-1 infections, demonstrating activity against subtype C and CRFO2_AG primary isolates. L-870812 is suitable for research applications involving replication-deficient HIV-1 Ba-L (env) pseudovirus, facilitating studies aimed at understanding HIV biology and developing therapeutic strategies. -
NF-κB Inhibitor, GPx Inhibitor, HIV Replication Inhibitor
α-MSH (11-13) acetate is a selective melanocortin-1 receptor ligand that functions as an inhibitor of NF-κB, GPx activity, and HIV replication. It induces an acute elevation of intracellular calcium levels under certain costimulation or pathway inhibition conditions. This compound effectively suppresses TNF-α-induced NF-κB activation, inhibits colony formation of Staphylococcus aureus and Candida albicans, and demonstrates potential in the study of infections related to these pathogens, as well as in traumatic brain injury, corneal epithelial wounds, and inflammatory bowel disease research. -
HIV Inhibitor
Sennoside A is an anthraquinone glycoside derived from the senna plant (Cassia angustifolia) that exhibits inhibitory activity against HIV-1. This compound demonstrates an IC50 value of 3.8 μM in preventing HIV-1 replication and effectively inhibits HIV-1 reverse transcriptase-related DNA polymerase and ribonuclease H, with IC50 values of 1.9 μM and 5.3 μM, respectively. Sennoside A serves as a valuable tool in antiviral research, particularly in studies of HIV-1 replication mechanisms and potential therapeutic interventions. -
HIV Inhibitor
Gomisin G is a lignan derived from Schisandra chinensis that acts as an anti-HIV agent with an EC50 of 0.006 μg/mL. It exhibits anti-liver cancer and anti-inflammatory properties while utilizing an AKT-cyclin D1 dependent mechanism to target triple-negative breast cancer cells by inhibiting phosphorylation rather than promoting apoptosis. Additionally, Gomisin G leads to G1 phase cell cycle arrest and inhibition of AKT phosphorylation. This compound is suitable for research applications focusing on HIV and various cancer types, including breast and liver cancers. -
HIV Protease Inhibitor
Ganoderic acid B is a triterpene derived from the medicinal mushroom Ganoderma lucidum, functioning as an inhibitor of HIV protease. This compound exhibits moderate inhibitory activity against HIV-1 protease, with an IC50 value of 170 μM, making it a potential candidate for research into antiviral therapies. Additionally, ganoderic acid B has demonstrated the ability to inhibit Epstein-Barr virus (EBV) antigen activation and may serve as a telomerase inhibitor, highlighting its broad potential in virology and cancer research applications. -
HIV Inhibitor
Salicylanilide is a known HIV inhibitor that targets HIV-1 integrase and reverse transcriptase. This compound exhibits significant antiviral potency, making it an important tool in the study of HIV biology and potential therapeutic strategies. Its multifaceted biological activities render it suitable for various research applications in the field of virology and antiviral drug development. -
HIV Inhibitor
Oxindole, also known as Indolin-2-one, functions as an HIV inhibitor. This compound is of significant interest in the development of kinase inhibitors, with 2-indolinone derivatives serving as promising lead compounds in various therapeutic applications. Its selective biological activity makes it a valuable reagent for research focused on HIV treatment and other related pathways in viral infections. -
HIV-1 Inhibitor
Thiamine disulfide is an oxidized dimer of vitamin B1 that serves as a potent inhibitor of HIV-1. Its primary mechanism involves the suppression of HIV-1 transactivator (Tat) activity, which is crucial for viral replication and pathogenesis. This compound is valuable in research applications focused on HIV-1-related studies and the development of antiviral strategies.
